All In Biotech

Drug Trial Radar · NCT07037875

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to D

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 523 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

523

Actual

Start

Sep 11, 2025

Primary completion

Sep 28, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
Cinclus Pharma Holding ABIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms more effectively than lansoprazole * Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate) * Causes any side effects during treatment * Has different effects depending on how much of the drug is in the blood * Works differently depending on participants' genes Participants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks. The study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group): * Linaprazan glurate 50 mg twice a day * Linaprazan glurate 50 mg once a day * Lansoprazole 30 mg once a day Everyone will take 2 tablets and 1 capsule by mouth daily for 8 weeks. Some tablets or capsules will be placebos (look like medicine but contain no active drug). Participants will: * Undergo an endoscopy in the beginning and after 4 weeks of treatment * If healing is not observed, another endoscopy may be done at 8 weeks * During the procedure, doctors will use a thin, flexible tube with a camera to look at the esophagus and take small tissue samples (biopsies) * Have blood and urine tests at clinic visits to check overall health * Receive electrocardiograms (ECGs) to monitor heart function * Complete daily questionnaires on an electronic device about symptoms and experiences

Conditions

  • GERD (Gastroesophageal Reflux Disease)

Interventions

  • Linaprazan glurate 50 mg Twice Daily (BID)Drug

    Participants in this group will receive a total daily dose of 100 mg of linaprazan glurate, administered as 50 mg in the morning and 50 mg in the evening. In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that matches the appearance of the lansoprazole capsule. In the evening, they take another 50 mg linaprazan glurate tablet, without any additional placebo.

  • Linaprazan Glurate 50 mg Once Daily (QD)Drug

    Participants in this group will receive a total daily dose of 50 mg of linaprazan glurate, taken once daily in the morning. In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that mimics the lansoprazole capsule. In the evening, they take a placebo tablet that mimics the appearance of the linaprazan glurate tablet.

  • Lansoprazole 30 mg Once Daily (QD)Drug

    Participants in this group will receive a total daily dose of 30 mg of lansoprazole, taken once daily in the morning. In the morning, they take one 30 mg lansoprazole capsule along with a placebo tablet that mimics the linaprazan glurate tablet. In the evening, they take another placebo tablet resembling linaprazan glurate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Healing of EE at Week 4 as assessed by endoscopy in participants with Baseline EE LA grades C/D.Time frame: From enrollment to the end of treatment at 4 weeks.

Locations

87 sites in 8 countries. Site status is shown where the registry gives one.

  • Medical Center Hera

    Kyustendil, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sveta Marina"

    Pleven, Bulgaria

  • Medical Center "Futuremeds"

    Plovdiv, Bulgaria

  • Multiprofile Hospital for Active Treatment "Sveti Panteleymon"

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sveti Ivan Rilski", Sofia, Clinic of Gastroenterology

    Sofia, Bulgaria

  • First Private Hospital Vratsa

    Vratsa, Bulgaria

  • Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski - 2003" OOD

    Dupnitsa, Dupnitsa, Bulgaria

  • Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD

    Gorna Oryahovitsa, Gorna Oryahovitsa, Bulgaria

  • Diagnosis - Consulting Centre 1

    Sliven, Sliven, Bulgaria

  • Medical Center "Orange"

    Sofia, Sofia City Province, Bulgaria

  • Multiprofile Hospital for Active Treatment - "Vita"

    Sofia, Sofia City Province, Bulgaria

  • Diagnostic and Consulting Center Alexandrovska

    Sofia, Sofia City Province, Bulgaria

  • Diagnostic Consultative Center - Focus-5

    Sofia, Sofia City Province, Bulgaria

  • Medical Center Hera

    Sofia, Sofia City Province, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL"

    Sofia, Sofia City Province, Bulgaria

  • University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov

    Sofia, Sofia City Province, Bulgaria

  • 20th Diagnostic Consultancy Center

    Sofia, Sofia City Province, Bulgaria

  • SurGal Clinic s.r.o.

    Brno, Czechia

  • University Hospital Brno

    Brno, Czechia

  • PreventaMed s.r.o.

    Olomouc, Czechia

  • Gastromedic s.r.o.

    Pardubice, Czechia

  • Hospital Prachatice a.s.

    Prachatice, Czechia

  • Endohope Morava s.r.o.

    Zábřeh, Czechia

  • Military Hospital Brno, Internal Department

    Brno, Brno, Czechia

  • Khozrevanidze's Clinic

    Batumi, Georgia

  • LTD Health

    Batumi, Georgia

  • JSC Georgian Clinics

    Kutaisi, Georgia

  • LTD Aversi Clinic

    Marneuli, Georgia

  • LTD Krol Medical Corporation

    Tbilisi, Georgia

  • The New Hospitals

    Tbilisi, Georgia

  • Israeli - Georgian Medical Research Clinic Healthycore LLC

    Tbilisi, Georgia

  • Janmrtelobis Sakhli LLC

    Tbilisi, Georgia

  • LLC Geo Hospitals

    Tbilisi, Georgia

  • K. Eristavi National Center of Experimental and Clinical Surgery JSC

    Tbilisi, Georgia

  • LTD Aversi Clinic

    Tbilisi, Georgia

  • LEPL The First University Clinic of Tbilisi State Medical University

    Tbilisi, Georgia

  • LTD The First Medical Center

    Tbilisi, Georgia

  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC

    Tbilisi, Georgia

  • Diakonie Hospital

    Mannheim, Baden-Wurttemberg, Germany

  • Medical Care Unit Dachau

    Dachau, Bavaria, Germany

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.